Combinaisons de thérapies anti-HER2: deux balles pour une même cible !GONCALVES, Anthony.Bulletin du cancer. 2012, Vol 99, Num 9, pp 813-814, issn 0007-4551, 2 p.Article

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing : Biologic and Methodologic ConsiderationsSAUTER, Guido; LEE, James; BARTLETT, John M. S et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1323-1333, issn 0732-183X, 11 p.Article

Maximizing Human Epidermal Growth Factor Receptor 2 Inhibition: A New Oncologic Paradigm in the Era of Targeted TherapyOLSON, Erin M.Journal of clinical oncology. 2012, Vol 30, Num 14, pp 1712-1714, issn 0732-183X, 3 p.Article

Biological properties of a human compact anti-ErbB2 antibodyDE LORENZO, Claudia; COZZOLINO, Rosanna; CARPENTIERI, Andrea et al.Carcinogenesis (New York. Print). 2005, Vol 26, Num 11, pp 1890-1895, issn 0143-3334, 6 p.Article

Breast Cancers Presenting Luminal B Subtype Features Show Higher Discordant Human Epidermal Growth Factor Receptor 2 Results Between Immunohistochemistry and Fluorescence In Situ HybridizationPARK, Seho; HYUNG SEOK PARK; JA SEUNG KOO et al.Cancer. 2012, Vol 118, Num 4, pp 914-923, issn 0008-543X, 10 p.Article

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?VAZ-LUISL, I; WINER, E. P; LIN, N. U et al.Annals of oncology. 2013, Vol 24, Num 2, pp 283-291, issn 0923-7534, 9 p.Article

Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancerYAMADA, Yoshiaki; NARUSE, Katsuya; HONDA, Nobuaki et al.Oncology reports. 2007, Vol 18, Num 1, pp 3-7, issn 1021-335X, 5 p.Article

Two Dimensions in Targeting HER2MOASSER, Mark M.Journal of clinical oncology. 2014, Vol 32, Num 19, pp 2074-2077, issn 0732-183X, 4 p.Article

ErbB2 Trafificking and Degradation Associated with K48 and K63 PolyubiquitinationMARX, Corina; HELD, Jason M; GIBSON, Bradford W et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 9, pp 3709-3717, issn 0008-5472, 9 p.Article

Pertuzumab: Optimizing HER2 BlockadeMETZGER-FILHO, Otto; WINER, Eric P; KROP, Ian et al.Clinical cancer research (Print). 2013, Vol 19, Num 20, pp 5552-5556, issn 1078-0432, 5 p.Article

Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner : Implications for progression of ErbB2-overexpressing tumorsLIXING ZHAN; BIN XIANG; MUTHUSWAMY, Senthil K et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5201-5208, issn 0008-5472, 8 p.Article

Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle BiopsiesLEBEAU, Annette; TURZYNSKI, Andreas; THOMSSEN, Christoph et al.Journal of clinical oncology. 2010, Vol 28, Num 20, pp 3264-3270, issn 0732-183X, 7 p.Article

Radionuclide therapy of HER2-positive microxenografts using a ¹⁷⁷Lu-labeled HER2-specific affibody moleculeTOLMACHEV, Vladimir; ORLOVA, Anna; WENNBORG, Anders et al.Cancer research (Baltimore). 2007, Vol 67, Num 6, pp 2773-2782, issn 0008-5472, 10 p.Article

HER2 testing in breast cancerCarlson, Robert W; Hammond, Elizabeth H; Allred, Craig et al.NCCN Task Force report. 2006, 1 cédéromBook

Surexpression de HER2: un dictat ? = Overexpression of HER2: a dictat?COTTU, P.Société Française de Sénologie et de Pathologie Mammaire. Journées. 2011, pp 168-173, isbn 978-2-8178-0248-0, 1Vol, 6 p.Conference Paper

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

Current and Emerging Targeted Therapies for Metastatic Breast CancerPEREZ, Edith A; SPANO, Jean-Philippe.Cancer. 2012, Vol 118, Num 12, pp 3014-3025, issn 0008-543X, 12 p.Article

Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patientsLIU, Zhe-Bin; LIU, Guang-Yu; YANG, Wen-Tao et al.Oncology reports. 2008, Vol 20, Num 4, pp 987-994, issn 1021-335X, 8 p.Article

ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistryTUOMINEN, Vilppu J; TOLONEN, Teemu T; ISOLA, Jorma et al.Histopathology. 2012, Vol 60, Num 5, pp 758-767, issn 0309-0167, 10 p.Article

Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancerLAUTERLEIN, Jens-Jacob L; PETERSEN, Eva R. B; OLSEN, Dorte Aa et al.Clinical chemistry and laboratory medicine. 2011, Vol 49, Num 5, pp 877-883, issn 1434-6621, 7 p.Article

Very high quantitative tumor HER2 content and outcome in early breast cancerJOENSUU, H; SPERINDE, J; ISOLA, J et al.Annals of oncology. 2011, Vol 22, Num 9, pp 2007-2013, issn 0923-7534, 7 p.Article

Extramammary Paget's disease : analysis of growth signal pathway from the human epidermal growth factor receptor 2 proteinOGAWA, Toru; NAGASHIMA, Yoji; WADA, Hidefumi et al.Human pathology. 2005, Vol 36, Num 12, pp 1273-1280, issn 0046-8177, 8 p.Article

Differential subcellular expression of protein kinase C betall in breast cancer: correlation with breast cancer subtypesGÖKMEN-POLAR, Yesim; MEHTA, Rutika; BADVE, Sunil et al.Breast cancer research and treatment. 2010, Vol 124, Num 2, pp 327-335, issn 0167-6806, 9 p.Article

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma : Possible implications for targeted therapyJINBIAO SHANG; YONGJIE SHUI; LIMING SHENG et al.Oncology reports. 2008, Vol 19, Num 2, pp 435-440, issn 1021-335X, 6 p.Article

Amplified in breast cancer 1 expression in breast cancerTHORAT, M. A; TURBIN, D; MORIMIYA, A et al.Histopathology. 2008, Vol 53, Num 6, pp 634-641, issn 0309-0167, 8 p.Article